First results of ADVANCE Study: clinical practice value
Abstract
The ADVANCE Study, started in early 2001, included 11140 patients aged over 55 years, with Type 2 diabetes mellitus (DM-2) and one more risk factor (RF): age 65 years and above, macro- or microvascular pathology in anamnesis, DM-2 duration over 10 years, etc. In patients with DM-2 and arterial hypertension (AH), blood pressure control could be achieved with perindopril + indapamide combination (4,0/1,25 mg), regardless of clinical and demographical parameters. Long-term combination therapy (4,5 years) was associated with substantial decrease in cardiovascular risk among DM-2 individuals, regardless of AH presence or absence and treatment characteristics.
References
1. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007: DOI:10.101.1016/S0140–6736(07)61303–8.
2. King H, Aubert R, Herman W. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414–31.
3. Haffner S, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34.
Review
For citations:
Nedogoda S.V. First results of ADVANCE Study: clinical practice value. Cardiovascular Therapy and Prevention. 2008;7(1):98-101. (In Russ.)
Views:
472
Email this article 
